Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04751682
Recruitment Status : Active, not recruiting
First Posted : February 12, 2021
Last Update Posted : June 22, 2021
Information provided by (Responsible Party):
Bharat Biotech International Limited